Takeda Pharmaceutical Company Limited
· ISIN: JP3463000004
· EQS - adhoc news
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News Takeda Pharmaceutical Company Limited
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
30 January 2025 09:31AM
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
News Release
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
CEO Christophe Weber to retire from Takeda in June 2026 after 12 years
Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process
OSAKA, Japan and CAMBRIDGE, Massachusetts, January 30, 2025 – Takeda (TSE...
Takeda Pharmaceutical Company Limited
30 January 2025 07:30AM
Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)
Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)
OSAKA, Japan, January 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below.
Revised Forecast for Full Year Consolidated Financials for the Fiscal...
Takeda Pharmaceutical Company Limited
31 October 2024 07:00AM
Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)
News Release
Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)
OSAKA, Japan, October 31, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below.
Revised Forecast for Full Year Consolidated Financia...
Takeda Pharmaceutical Company Limited
09 May 2024 08:00AM
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
OSAKA, Japan, May 9, 2024 – Takeda (TSE:4502/NYSE:TAK) announced that its Board of Directors today approved a significant multi-year program focused on organizational agility, spending efficiencies and leveraging the company’s capabilities in data, digital and technology (DD&T). The program aims to improve growth through continued advancement o...
Takeda Pharmaceutical Company Limited
26 October 2023 08:00AM
Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
OSAKA, Japan, October 26, 2023 - Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2024, as below.
Revised Forecast for Full Year Consolidated Financials for the ...
Takeda Pharmaceutical Company Limited
03 February 2022 07:00AM
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
Osaka, Japan, February 3, 2022 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2022, as below.
1. Revised Forecast for Full Year Conso...
Takeda Pharmaceutical Company Limited
29 October 2020 07:01AM
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
Osaka, Japan, October 29, 2020 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced today, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2021, as below.
1. Revised Forecast for Full Year Cons...
Takeda Pharmaceutical Company Limited
24 August 2020 09:00AM
Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
Takeda to Divest its Japan Consumer Health Care Business Unit
to Blackstone for JPY 242.0 Billion
Transaction further sharpens Takeda's focus on five key business areas
Consumer Health Care Business to continue serving consumers in Japan and Asia under new owner
Osaka, Japan, August 24, 2020 - Takeda Pharmaceutical Company Limited (TSE:4502/NYS...
Takeda Pharmaceutical Company Limited
31 July 2020 08:00AM
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
Osaka, Japan, July 31, 2020 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced today, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2021, as below.
1. Revised Forecast for Full Year Consoli...
Takeda Pharmaceutical Company Limited
More Takeda Pharmaceutical Company Limited related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN